Please use this identifier to cite or link to this item:
Title: A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
Issue Date: Oct-2015
Citation: Clin Kidney J.2015 Oct;(8)5:503-10
Abstract: Patients with primary membranous nephropathy (MN) and persistent nephrotic syndrome have a high risk of progression to end-stage renal disease. The Ponticelli protocol (steroids with alkylating agents) is the most effective immunosuppressive therapy for this condition, but it has severe adverse effects. Tacrolimus and rituximab have demonstrated efficacy for remission of nephrotic syndrome in MN with a safer profile. However, the published evidence is largely based on small or short-term observational studies, historical cohorts, comparisons with conservative therapy or clinical trials without appropriate control groups, and there is no head-to-head comparison with the Ponticelli protocol.
PMID: 26413273
Rights: openAccess
ISSN: 2048-8505
Appears in Collections:Hospitales > H. U. Fundación Alcorcón > Artículos

Files in This Item:
File Description SizeFormat 
PMC4581392.pdf519.15 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.